Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 1 min 4 sec ago

Zynex Announces Brian Alleman as Chief Financial Officer

Mon, 07/21/2014 - 15:05
LONE TREE, CO--(Healthcare Sales & Marketing Network) - Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological d...
Devices, Neurology, Personnel
Zynex, NeuroDiagnostics, electrotherapy

Anacor Pharmaceuticals and Sandoz Enter Into an Agreement for the Commercialization of KERYDIN in the United States

Mon, 07/21/2014 - 15:02
Anacor Will Host a Conference Call Today at 8:00 a.m. EDT / 5:00 a.m. PDT PALO ALTO, Calif.--(Healthcare Sales & Marketing Network)--Anacor Pharmaceuticals, Inc. (ANAC) today announced that it has entered into an exclusive agreement with Sandoz Inc., a ...
Biopharmaceuticals, Dermatology, Distribution
Anacor Pharmaceuticals, Sandoz, KERYDINTM, tavaborole

MicroCHIPS, Inc. appoints Cheryl R. Blanchard, Ph.D., as Chief Executive Officer

Mon, 07/21/2014 - 15:00
Industry veteran to lead next stage of commercialization for implantable drug delivery devices, with near-term focus on women's health WALTHAM, Mass.--(Healthcare Sales & Marketing Network)--MicroCHIPS, Inc., a developer of implantable drug delivery dev...
Devices, Drug Delivery, Personnel
MicroCHIPS

AngioDynamics Awarded Novation Innovative Technology Contract Covering BioFlo PICCs and BioFlo Ports

Mon, 07/21/2014 - 14:56
ALBANY, N.Y., July 21, 2014 -- (Healthcare Sales & Marketing Network) -- AngioDynamics (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today rece...
Devices, Group Purchasing
AngioDynamics, Novation, PICC

Surgeons of the University Hospital Essen Complete World's First Robotic-Assisted Cancer Surgery with Medrobotics' Flex(R) System

Mon, 07/21/2014 - 14:53
ESSEN, Germany--(Healthcare Sales & Marketing Network)--Leading surgeons of the Ear, Nose and Throat Clinic at the University Hospital Essen completed the world’s first robotic-assisted cancer procedures with the Medrobotics’ Flex® System. Professor St...
Devices, Oncology, Surgery
Medrobotics, robotic surgery

Durata Therapeutics Announces the U.S. Launch of DALVANCE(TM)

Fri, 07/18/2014 - 12:08
CHICAGO, July 18, 2014 -- (Healthcare Sales & Marketing Network) -- Durata Therapeutics, Inc. (DRTX) announced today that DALVANCE (dalbavancin) for injection is now available for use to treat adult patients with acute bacterial skin and skin structure inf...
Biopharmaceuticals, Product Launch
Durata Therapeutics, DALVANCE, dalbavancin, ABSSSI

Bausch + Lomb's VICTUS(R) Femtosecond Laser Platform Receives 510(k) Clearance from FDA for Lens Fragmentation Procedure

Thu, 07/17/2014 - 13:03
LAVAL, Quebec , July 17, 2014 (Healthcare Sales & Marketing Network) -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that its wholly owned subsidiary, Bausch + Lomb has received 510(k) clearance from the U.S. Food an...
Devices, Ophthalmology, FDA
Valeant Pharmaceuticals, Bausch + Lomb, VICTUS , Femtosecond Laser

Edico Genome Raises $10 Million in Series A Financing to Commercialize DRAGEN Chip to Overcome Sequencing Data Analysis Bottleneck

Thu, 07/17/2014 - 12:55
Led by Qualcomm, Gregory Lucier Makes First Investment after Leading Life Technologies SAN DIEGO, July 17, 2014 -- (Healthcare Sales & Marketing Network) -- Edico Genome announced today that it has raised $10 million in a Series A financing to commerci...
Devices, Diagnostics, Venture Capital
Edico Genome, DRAGEN Bio-IT Processor

Salix and Pharming Announce FDA Approval of RUCONEST(R) for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)

Thu, 07/17/2014 - 12:47
RUCONEST® (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg IS The First and Only Recombinant Treatment Option for Adult and Adolescent Patients Suffering from Hereditary Angioedema RALEIGH, N.C. & LEIDEN, The Netherlands--(Healthcare Sales & Marketin...
Biopharmaceuticals, FDA
Salix Pharmaceuticals, Pharming Group, RUCONEST, hereditary angioedema

Covidien Makes Liver Tumor Ablation More Predictable

Wed, 07/16/2014 - 13:09
DUBLIN, Ireland--(Healthcare Sales & Marketing Network)--Overcoming a significant roadblock to predictable ablation of soft tissue, Covidien plc (COV) has unveiled an advanced ablation system that offers physicians predictable results regardless of the tar...
Devices, Surgery, Product Launch
Covidien, Emprint Ablation System, Thermosphere, ablation

Pfizer Announces Positive Top-Line Results From Phase 3 Study Of NONACOG ALFA (BeneFIX(R)) Once-Weekly Prophylaxis For Hemophilia B

Wed, 07/16/2014 - 13:02
Once-Weekly Prophylaxis Treatment with BeneFIX® Significantly Reduced Annualized Bleeding Rate Compared to On-Demand Treatment NEW YORK--(Healthcare Sales & Marketing Network)--Pfizer Inc. (PFE) today announced the positive results of a Phase 3 stud...
Biopharmaceuticals
Pfizer, BeneFIX, Factor IX, hemophilia B

Virobay Completes $8 Million Series B Preferred Stock Financing

Wed, 07/16/2014 - 12:56
MENLO PARK, Calif., July 16, 2014 -- (Healthcare Sales & Marketing Network) -- Virobay, Inc., a clinical stage pharmaceutical company with a platform of cathepsin protease inhibitors being developed for the treatment of neuropathic pain, autoimmune diseas...
Biopharmaceuticals, Venture Capital
Virobay, VBY-036, neuropathic pain

MediWound Announces NexoBrid Marketing Approval From Israeli Ministry of Health

Wed, 07/16/2014 - 12:53
Market Launch Planned for This Quarter YAVNE, Israel, July 16, 2014 -- (Healthcare Sales & Marketing Network) -- MediWound Ltd. (MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
Biopharmaceuticals, Wound Care, Regulatory
MediWound, NexoBrid, debridement

First Patient Enrolment in MASCOT Registry Represents Major Milestone for COMBO(TM) Dual Therapy Stent and OrbusNeich's Clinical Programme

Wed, 07/16/2014 - 12:46
2,500-patient, 50-center study is the largest post-marketing registry on the safety and effectiveness of the COMBO Stent HONG KONG, July 16, 2014 -- (Healthcare Sales & Marketing Network) -- OrbusNeich today announced that the first patient has been en...
Devices, Interventional Cardiology
OrbusNeich, COMBO Dual Therapy Stent, Sirolimus, drug eluting stent

ACADIA Pharmaceuticals Announces Appointment of Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer

Tue, 07/15/2014 - 19:23
SAN DIEGO--(Healthcare Sales & Marketing Network)--ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central...
Biopharmaceuticals, Personnel
ACADIA Pharmaceuticals

InspireMD Appoints Dr. James Barry as Chief Operating Officer

Tue, 07/15/2014 - 13:15
Strengthens Leadership Team with Addition of Experienced Medical Device Executive BOSTON, July 15, 2014 -- (Healthcare Sales & Marketing Network) -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in emboli...
Devices, Interventional, Personnel
InspireMD, embolic protection, MGuard

CutisPharma Appoints Neal Muni, MD, MSPH as President

Tue, 07/15/2014 - 13:10
WILMINGTON, Mass., July 15, 2014 -- (Healthcare Sales & Marketing Network) -- CutisPharma announced today that it has appointed Neal Muni, MD, MSPH as President and member of the Board of Directors. Dr. Muni will assume responsibility for overseeing the c...
Biopharmaceuticals, Personnel
CutisPharma

Mystic Pharmaceuticals Unveils The Next Generation Of Patient-Centric Sublingual Drug Delivery Devices

Tue, 07/15/2014 - 13:05
AUSTIN, Texas--(Healthcare Sales & Marketing Network)--Mystic Pharmaceuticals, Inc. today announced the availability of its Javelin Sublingual™ drug delivery devices. Javelin Sublingual dispensers utilized Mystic’s VersiDoser® and VRx2™ platform techno...
Biopharmaceuticlas, Drug Delivery, Product Launch
Mystic Pharmaceuticals, Javelin Sublingual, VersiDoser, VRx2

Pradaxa(R) (dabigatran etexilate) Now Available in the UK for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and Prevention of Recurrence

Tue, 07/15/2014 - 12:59
Pradaxa® is as effective as warfarin in the treatment and secondary prevention of DVT and PE with significantly fewer major, or clinically relevant non-major bleeds, compared to warfarin1,2 BRACKNELL, England, July 15, 2014 -- (Healthcare Sales & Ma...
Biopharmaceuticals, Regulatory
Boehringer Ingelheim, Pradaxa, dabigatran, DVT, Pulmonary Embolism

FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer

Tue, 07/15/2014 - 12:44
SOUTH SAN FRANCISCO, Calif.--(Healthcare Sales & Marketing Network)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics Lic...
Biopharmaceuticals, Oncology, FDA
Genentech, Roche Group, Avastin, bevacizumab, cervical cancer

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong